PDL BioPharma Income Statement
View: Annual | Quarterly
| Dec 08 | Dec 07 | Dec 06 | |
|---|---|---|---|
| Revenue | 294.3 | 258.9 | 414.8 |
| Cost of Goods Sold | -- | -- | 86.3 |
| Gross Profit | -- | -- | 328.5 |
| Gross Profit Margin | 0.0% | 0.0% | 79.2% |
| SG&A Expense | 51.5 | 67.4 | 120.9 |
| Depreciation & Amortization | 22.5 | 64.5 | 75.7 |
| Operating Income | 257.6 | (5.4) | (116.2) |
| Operating Margin | 87.5% | -- | -- |
| Nonoperating Income | 0.0 | 0.0 | 0.0 |
| Nonoperating Expenses | 0.7 | -- | -- |
| Income Before Taxes | 243.4 | (19.1) | (129.3) |
| Income Taxes | 5.0 | 0.2 | 0.8 |
| Net Income After Taxes | 238.4 | (19.4) | (130.0) |
| Continuing Operations | 238.4 | (19.4) | (130.0) |
| Discontinued Operations | (170.0) | (1.7) | -- |
| Total Operations | 68.4 | (21.1) | (130.0) |
| Total Net Income | 68.4 | (21.1) | (130.0) |
| Net Profit Margin | 23.2% | -- | -- |
| Diluted EPS from Total Net Income ($) | 0.47 | (0.18) | (1.14) |
| Dividends per Share | 0.00 | 0.00 | 0.00 |
© 2009 Morningstar, Inc. Financial Data provided by
